NOTICE - IMPORTANT SHAREHOLDER INVESTIGATION UPDATE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: QUINTANA ENERGY SERVICES, INC. (NYSE - QES), STEMLINE THERAPEUTICS, INC. (NASDAQ - STML) AND resTORbio, Inc. (NasdaqGS - TORC)

BALA CYNWYD, PA / ACCESSWIRE / May 19, 2020 / Brodsky & Smith, LLC reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other violations of federal and state law with respect to proposed acquisition transactions. If you own shares of any of the below-referenced stocks and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, or calling toll free 877-534-2590. There is no cost or financial obligation to you.

QUINTANA ENERGY SERVICES, INC. (NYSE:QES)

Under the terms of the agreement, Quintana shareholders will receive only 0.4844 shares of KLX common stock for QES share they own. The investigation concerns whether the Quintana Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether KLX is underpaying for the Company. For example, at least one analyst has set a target price for Quintana of $9.00 per share.

Additional information can be found at http://www.brodskysmith.com/cases/quintana-energy-services-inc-nyse-qes/,, or call 877-534-2590. No cost or obligation to you.

STEMLINE THERAPEUTICS, INC. (NASDAQ:STML)

Under the terms of the agreement, Stemline shareholders will receive only $12.50 consisting of an upfront payment of $11.50 in cash and a contingent value right appraised at $1.00 for each share of Stemline they own. The investigation concerns whether the Stemline Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Menarini is underpaying for the Company. For example, at least one analyst has set a target price for Stemline of $33.00 per share.

Additional information can be found at http://www.brodskysmith.com/cases/stemline-pharmaceuticals-inc-nasdaqgs-stml/, or call 877-534-2590. No cost or obligation to you.

resTORbio, Inc. (NasdaqGS:TORC)

Under the terms of the agreement, Adicet shareholders are expected to own approximately 75% of the combined company and resTORbio shareholders are expected to own only 25%.

Additional information can be found at http://www.brodskysmith.com/cases/restorbio-inc-nasdaqgs-torc/, or call 877-534-2590. No cost or obligation to you.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Brodsky & Smith, LLC